Q1 2026 Management View "As we move through 2026, next-generation cell therapy is shifting from promise to proof." (CEO David Chang) "In this 24-patient analysis, cema-cel achieved a 58.3% MRD ...

CEO Michael S. Exton stated, "When we entered 2025, if you recall, we're still in the early days of our strategic pivot to being an R&D-focused company. And now in the second half of the year, I can ...

Here are the average operating expenses per case for surgery centers organized by region, according to VMG Health’s 2009 Intellimarker.

Orthopedic-driven ASCs (facilities with greater than 50 percent of their case volume in orthopedics) commit an average of 71.3 percent of their net revenue to operating expenses, according to VMG ...